| UCLA |
|
UCLA |
X-linked Chronic Granulomatous Disease |
Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease |
Active, not recruiting |
|
| UC Davis & UCSD |
|
Viacyte |
Type 1 diabetes |
An Open-Label, First-in-Human, Study Evaluating the Safety, Tolerability, and Efficacy of VC-02 Combination Product in Subjects with Type 1 Diabetes Mellitus and Hypoglycemia Unawareness |
No longer active |
|
| UCSF |
|
Talaris |
Transplanted Organ Rejection |
A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation (FREEDOM-1) |
No longer active |
|
| UCI |
|
SanBio |
Stroke |
Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke |
No longer active |
|
| UCI |
|
ReNeuron Limited |
Stroke |
A Randomized, Placebo-Controlled Study of the Efficacy and Safety of Intracerebral Stem Cells (CTX0E03) in Subjects with Disability Following an Ischemic Stroke (PISCES III) |
No longer active |
|
| UCSD |
|
Neuralstem |
Spinal Cord Injury |
Safety Study of Human Spinal Cord-derived Neural Stem Cell Transplantation for the Treatment of Chronic SCI |
Recruiting |
|
| UCSD |
|
Asterias Biotherapeutics |
Spinal Cord Injury |
Dose Escalation Study of AST-OPC1 in Spinal Cord Injury |
No longer active |
|
| UC Davis |
|
UC Davis/CIRM |
Spina bifida |
Phase 1/2a Trial of Placental Mesenchymal Stem Cells for Repair of Fetal Myelomeningocele |
Recruiting |
|
| UCSD |
|
Fate Therapeutics |
Solid tumors |
FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors |
No longer active |
|
| UC Davis & UCSD & UCI & UCSF & City of Hope |
|
Pact Pharma & CIRM |
Solid tumors |
A Phase 1a/1b, Open Label First In Human Study Of The Safety, Tolerability And Feasibility Of Gene Edited Autologous NeoTCR T Cells (NeoTCR-P1) Administered As A Single Agent Or In Combination With Anti PD-1 To Patients With Locally Advanced Or Metastatic |
No longer active |
|
| UCLA |
|
UCLA |
Sickle Cell Disease |
Stem Cell Gene Therapy for Sickle Cell Disease |
Recruiting |
|
| City of Hope |
|
City of Hope |
Sickle Cell Disease |
A Pilot Study to Evaluate the Safety and Feasibility of Induction of Mixed Chimerism in Sickle Cell Disease Patients with COH-MC-17: a Non-Myeloablative, Conditioning Regimen and CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant |
Recruiting |
|
| UCSF |
|
bluebird bio |
Sickle Cell Disease |
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease |
No longer active |
|
| City of Hope |
|
City of Hope |
Sickle Cell Disease |
Safety of Blood Stem Cell Mobilization With Plerixafor in Patients With Sickle Cell Disease (PISMO) |
Recruiting |
|
| UCSF and UC Davis |
|
Bioverativ Therapeutics, Inc |
Sickle Cell Disease |
A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients with Severe Sickle Cell Disease |
No longer active |
|
| UCSF |
|
Editas Medicine Inc. |
Sickle Cell Disease |
A Phase 1/2 Study to Evaluate the Safety and Efficacy of a Single Dose of Autologous Clustered Regularly Interspaced Short Palindromic Repeats Gene-edited CD34+ Human Hematopoietic Stem and Progenitor Cells (EDIT-301) in Subjects With Severe Sickle Cell D |
Recruiting |
|
| UCSF |
|
CIRM & NHLBI |
Severe sickle cell disease |
Transplantation of CRISPRCas9 Corrected Hematopoietic Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease |
Active, not recruiting |
|
| UCSF |
|
Stanford University |
Severe Combined Innunodeficiency (SCID) |
AMG191 Conditioning/CD34+CD90 Stem Cell Transplant Study for SCID Patients |
Recruiting |
|
| UCSF |
|
Jasper Therapeutics |
Severe Combined Immunodeficiency syndrome |
A Phase 1 study to evaluate the safety and tolerability of tandemly-purified allogeneic CD34+CD90+ HSC administered following conditioning with JSP 191 to achieve engraftment and immune reconstitution in patients with SCID |
Recruiting |
|
| UCLA |
|
Orchard Therapeutics |
Severe Combined Immunodeficiency (SCID) |
Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency |
Active, not recruiting |
|
| UCLA |
|
UCLA |
Severe Combined Immunodeficiency (SCID) |
Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) |
Active, not recruiting |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies |
No longer active |
|
| UCSD |
|
Calibr |
Relapsed/Refractory B-cell Lymphomas |
Long term follow-up study for patients administered CLBR001 , a CAR-T cell |
No longer active |
|
| UCSF |
|
Poseida Therapeutics, Inc. |
Prostate cancer |
A Phase 1 Dose Escalation and Expanded Cohort Study of P‑PSMA‑101 in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) |
No longer active |
|
| UC Davis |
|
Cabaletta |
Pemphigus Vulgaris |
Phase 1, Open-label, Safety and Dosing Study of Autologous Desmoglein 3 Chimeric Autoantibody Receptor T Cells (DSG3-CAART) in Subjects with Active, Anti-DSG3, Mucosal-dominant Pemphigus Vulgaris |
Recruiting |
|
| UCI |
|
Brain Neurotherapy Bio |
Parkinson's |
Open-Label Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2- GDNF) in Parkinson’s Disease |
Active, not recruiting |
|
| UCSD |
|
Aivita |
Ovarian and Fallopian Tube Carcinoma |
Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas |
Active, not recruiting |
|
| City of Hope |
|
City of Hope |
Neurodegenerative Disorder |
Acquisition of Skin Biopsy Samples from Healthy Volunteers and Patients Diagnosed with X-Linked Adrenoleukodystrophy (ALD), Canavan Disease (CD) and other Inherited Leukodystrophies |
Recruiting |
|
| UCI |
|
Cartesian Therapeutics |
MYASTHENIA GRAVIS (MG) |
Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) |
Recruiting |
|
| UC Davis |
|
Pluristem Ltd. |
Muscle Injury - hip fracture |
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty |
Recruiting |
|
| UC Davis |
|
Capricor Therapeutics |
Muscle - Duchenne Muscular Dystrophy |
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) |
No longer active |
|
| UCSF & UC Davis |
|
Poseida Therapeutics, Inc. |
Multiple Myeloma |
Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) |
No longer active |
|
| UCSF |
|
Cellectis, SA |
Multiple Myeloma |
Phase I, open label dose‐escalation study to evaluate the safety, expansion, persistence and clinical activity of UCARTCS1A (allogeneic engineered T‐cells expressing anti‐CS1 chimeric antigen receptor), administered in patients with Relapsed/Refractory Mu |
No longer active |
|
| UC Davis |
|
Medeor Therapuetics |
Kidney Transplant |
Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants |
No longer active |
|
| UC Davis |
|
AlloVir |
Kidney transplant |
Phase 2 multicenter, randomized, double-blind, placebo-controlled, multiple dosing interval, 3-period study of the safety, tolerability and effectiveness of adoptively transferred Viralym-M multivirus-specific T cells in kidney transplant recipients with |
No longer active |
|
| UCI & UC Davis |
|
Humacyte |
Kidney Failure |
An Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
No longer active |
|
| UCI & UC Davis |
|
Humacyte |
Kidney failure |
A Phase 3 Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel With That of an Autologous Arteriovenous Fistula in Subjects With End Stage Renal Disease |
Active, not recruiting |
|
| UCI |
|
Pluristem Ltd. |
Intubated COVID-19 patients |
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase II Study to Evaluate the Efficacy and Safety of Intramuscular Injections of PLX PAD for the Treatment of Severe COVID-19 |
No longer active |
|
| City of Hope |
|
Children’s Hospital Los Angeles |
Infection After Stem Cell Transplant |
Antiviral Cellular Therapy for Enhancing T-cell Reconstitution |
Recruiting |
|
| UCI & UC Davis |
|
Celularity, Inc. |
Hospitalized COVID-19 patients |
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19 |
Active, not recruiting |
|
| City of Hope & UCLA |
|
City of Hope |
HIV/AIDS |
Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients |
No longer active |
|
| UCLA |
|
Calimmune |
HIV/AIDS |
Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection |
No longer active |
|
| UCSF |
|
Case Western Reserve University |
HIV |
A Comparative Study of Autologous CD4+ T Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728 versus ex vivo Expanded Unmodified Autologous CD4+ T Cells in Treated HIV-1 Infected Subjects (TRAILBLAZER) |
No longer active |
|
| UC Davis |
|
Eureka Therapeutics |
Hepatocellular Carcinoma |
An Open-Label, Dose Escalation, Multi-Center Phase I/II Research Trial to Assess the Safety of ET140203 T Cells and Determine the Recommended Phase II Dose (RP2D) in Adults With Advanced Hepatocellular Carcinoma (HCC) |
Recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia B |
Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B |
Recruiting |
|
| City of Hope |
|
Sangamo Therapeutics |
Hemophilia A |
Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A |
Recruiting |
|
| UC Davis |
|
Orca Biosystems, Inc. |
Hematologic Malignancies |
A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived from Mobilized Peripheral Blood, With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UC Davis |
|
Orca Biosystems Inc. |
Hematologic Malignancies |
A Study of Engineered Donor Grafts (TregGraft) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies |
Recruiting |
|
| UC Davis |
|
Atara Bio |
Hematologic Malignancies |
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associated Diseases |
Recruiting |
|
| UCSD |
|
Mesoblast |
Heart Failure |
The Purpose of This Study is to Evaluate the Efficacy and Safety of a Allogeneic Mesenchymal Precursor Cells (CEP-41750) for the Treatment of Chronic Heart Failure |
No longer active |
|
